

# FDA drafts guidance on patient labeling information for LASIK devices

August 1 2022

---



In a draft guidance document issued July 28 by the U.S. Food and Drug

Administration, content and formatting recommendations are presented for patient labeling information for laser-assisted in situ keratomileusis (LASIK) devices.

Owing to concerns that some patients are not receiving and/or understanding information regarding the risks and benefits of LASIK devices, the authors offer content and formatting suggestions for patient labeling information. The labeling recommendations are intended to enhance the physician-patient discussion of the benefits and risks of LASIK.

The suggested format and content of patient labeling should include a description of the eye and the [surgery](#) and explanation of what LASIK is and what the laser does. Indications for use should be presented, and there should be discussion of the benefits, alternatives, contraindications, warnings, and precautions, as well as a description of patient risks. In addition, the labeling should include a description of what the patient should expect before, during, and after surgery, as well as relevant clinical study information, while providing specific context about the LASIK device to be used in the procedure.

"The FDA recommends that a copy of the patient decision checklist be provided to the patient so that the patient can refer back to this important [information](#)," the authors write. "The FDA also encourages device manufacturers to develop a plan to ensure that [patients](#) are adequately informed of the risks of LASIK."

**More information:** [More Information](#)

Copyright © 2022 [HealthDay](#). All rights reserved.

Citation: FDA drafts guidance on patient labeling information for LASIK devices (2022, August

1) retrieved 18 April 2024 from

<https://medicalxpress.com/news/2022-08-fda-guidance-patient-lasik-devices.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.